Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00211744
Status:
COMPLETED
Last Update Posted:
2018-05-30
First Post:
2005-09-13
Brief Title:
Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder
Sponsor:
Montefiore Medical Center
Organization:
Montefiore Medical Center
Study Overview
Official Title:
Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder
Status:
COMPLETED
Status Verified Date:
2018-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A 12-week program to examine the effectiveness of topiramate in adjunctive treatment for adults with obsessive-compulsive disorder and who are currently on serotonin reuptake inhibitor medications ages 18-65
Detailed Description:
The Compulsive Impulsive and Anxiety Disorders Program at the Mount Sinai School of Medicine is conducting a study of Topiramate Topamax added to an SSRI for the management of treatment-resistant Obsessive-Compulsive Disorder The purpose of the study is to evaluate the safety and efficacy of Topiramate versus placebo added to a selective serotonin reuptake inhibitor SRI in patients with treatment resistant OCD The program is 12 weeks in duration and involves regular visits with a psychiatrist as well as complete psychiatric and medical evaluations Treatment and medication for the study will be provided free of chargeParticipants must be between the ages of 18 and 65 and have an onset of OCD at least 1 year prior to screening In addition participants must be taking a clinically effective dose of an SSRI for at least 3 months and must maintain their current dose throughout the study Participants must not have a primary OCD symptom of hoarding
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None